Sumitomo Mitsui DS Asset Management Company Ltd Buys 6,290 Shares of DexCom, Inc. (NASDAQ:DXCM)

Sumitomo Mitsui DS Asset Management Company Ltd increased its stake in DexCom, Inc. (NASDAQ:DXCM) by 15.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,263 shares of the medical device company’s stock after buying an additional 6,290 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in DexCom were worth $3,676,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Geode Capital Management LLC raised its position in shares of DexCom by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 9,937,604 shares of the medical device company’s stock worth $664,056,000 after acquiring an additional 214,136 shares in the last quarter. Jennison Associates LLC boosted its position in shares of DexCom by 10.3% during the fourth quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company’s stock valued at $594,455,000 after purchasing an additional 710,858 shares in the last quarter. Groupama Asset Managment grew its stake in DexCom by 1.1% in the third quarter. Groupama Asset Managment now owns 2,851,556 shares of the medical device company’s stock worth $1,912,000 after purchasing an additional 31,358 shares during the period. Westfield Capital Management Co. LP raised its holdings in DexCom by 44.6% in the third quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock worth $190,532,000 after purchasing an additional 876,739 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in DexCom by 11.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 2,734,155 shares of the medical device company’s stock valued at $183,298,000 after buying an additional 288,381 shares during the period. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Price Performance

Shares of DXCM opened at $88.08 on Monday. The firm has a fifty day simple moving average of $81.76 and a two-hundred day simple moving average of $75.36. The firm has a market cap of $34.40 billion, a PE ratio of 52.74, a P/E/G ratio of 2.26 and a beta of 1.14. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on DXCM shares. Canaccord Genuity Group upped their target price on shares of DexCom from $89.00 to $99.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Citigroup upped their price objective on shares of DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Leerink Partners lowered their target price on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Wells Fargo & Company upped their price target on DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Finally, Redburn Atlantic upgraded DexCom from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $85.00 to $115.00 in a research note on Monday, February 3rd. Four investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $98.41.

Insider Buying and Selling

In other DexCom news, EVP Jereme M. Sylvain sold 2,090 shares of the business’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the sale, the executive vice president now directly owns 83,526 shares in the company, valued at $7,259,244.66. The trade was a 2.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Sadie Stern sold 4,259 shares of the company’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the sale, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at $5,320,178.16. The trade was a 5.64 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 42,342 shares of company stock valued at $3,628,069 over the last 90 days. Company insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.